Medicenna Therapeutics Corp (MDNAF)

$0.59 -0.01 (-2.15%)
Market Cap 50.05M
Revenue (ttm) 0.00
Net Income (ttm) -8.48M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 51,900
Avg Vol 128,934
Day's Range N/A - N/A
Shares Out 83.41M
Stochastic %K 7%
Beta 1.81
Analysts Strong Sell
Price Target $2.96

Company Profile

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, a long-acting interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; MDNA209, an IL-2/IL-15...

Industry: Biotechnology
Sector: Healthcare
Phone: 416 648 5555
Address:
2 Bloor Street West, Suite 903 7th Floor, Toronto, Canada
Lytnup
Lytnup Feb. 20 at 3:41 PM
$MDNAF Hope everyone has a fabulous weekend; I am done bid-sitting for now (continuing to DCA as funds allow), and am off to prune the fruit trees. Would be great if Dr. Merchant finally finds a partner for his pipeline; looks like he’ll be busy with conferences over the next month or two.
0 · Reply
theoptionsplug
theoptionsplug Feb. 20 at 7:08 AM
THINGS TO WATCH, 2/20/26 👁️ $LAMR $AU $QCOM $MDNAF $SPY
3 · Reply
Lytnup
Lytnup Feb. 19 at 11:42 PM
$MDNAF Medicenna’s IR team has definitely upped their placement strategy. Hopefully it gets noticed. https://www.linkedin.com/posts/medicenna-therapeutics-corp-_science-primer-bizaxofusp-in-deadliest-brain-activity-7430066191622361089-qwDn?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsnC8EBAcKQyUEEvVrkPzTEpnlOSa2bgnk
2 · Reply
Gobblin
Gobblin Feb. 19 at 9:36 PM
$MDNAF
0 · Reply
Gobblin
Gobblin Feb. 18 at 11:27 PM
$MDNAF - Feb 19
1 · Reply
Gobblin
Gobblin Feb. 18 at 9:41 PM
$MDNAF - partnership meetings . Hmmm….
0 · Reply
Dipper2013
Dipper2013 Feb. 18 at 1:57 PM
$MDNAF
0 · Reply
Lytnup
Lytnup Feb. 18 at 1:17 PM
$MDNAF Anybody else having a hard time seeing PRs on the company’s website? https://ir.medicenna.com/node/10361/pdf
0 · Reply
Lytnup
Lytnup Feb. 17 at 3:43 PM
$MDNAF I was also unaware that Dr Gwynne joined the team last November https://www.linkedin.com/posts/william-d-gwynne-phd-75a722132_excited-to-share-that-ive-joined-medicenna-activity-7396329961076215808-TlTW?utm_medium=ios_app&rcm=ACoAAAsnC8EBAcKQyUEEvVrkPzTEpnlOSa2bgnk&utm_source=social_share_send&utm_campaign=copy_link
1 · Reply
Lytnup
Lytnup Feb. 17 at 12:55 PM
$MDNAF Here’s to getting new eyes on Medicenna’s pipeline & promise https://open.substack.com/pub/davidbakke/p/from-biology-outpaced-to-execution?r=10wt7d&utm_medium=ios
0 · Reply
Latest News on MDNAF
No data available.
Lytnup
Lytnup Feb. 20 at 3:41 PM
$MDNAF Hope everyone has a fabulous weekend; I am done bid-sitting for now (continuing to DCA as funds allow), and am off to prune the fruit trees. Would be great if Dr. Merchant finally finds a partner for his pipeline; looks like he’ll be busy with conferences over the next month or two.
0 · Reply
theoptionsplug
theoptionsplug Feb. 20 at 7:08 AM
THINGS TO WATCH, 2/20/26 👁️ $LAMR $AU $QCOM $MDNAF $SPY
3 · Reply
Lytnup
Lytnup Feb. 19 at 11:42 PM
$MDNAF Medicenna’s IR team has definitely upped their placement strategy. Hopefully it gets noticed. https://www.linkedin.com/posts/medicenna-therapeutics-corp-_science-primer-bizaxofusp-in-deadliest-brain-activity-7430066191622361089-qwDn?utm_source=share&utm_medium=member_ios&rcm=ACoAAAsnC8EBAcKQyUEEvVrkPzTEpnlOSa2bgnk
2 · Reply
Gobblin
Gobblin Feb. 19 at 9:36 PM
$MDNAF
0 · Reply
Gobblin
Gobblin Feb. 18 at 11:27 PM
$MDNAF - Feb 19
1 · Reply
Gobblin
Gobblin Feb. 18 at 9:41 PM
$MDNAF - partnership meetings . Hmmm….
0 · Reply
Dipper2013
Dipper2013 Feb. 18 at 1:57 PM
$MDNAF
0 · Reply
Lytnup
Lytnup Feb. 18 at 1:17 PM
$MDNAF Anybody else having a hard time seeing PRs on the company’s website? https://ir.medicenna.com/node/10361/pdf
0 · Reply
Lytnup
Lytnup Feb. 17 at 3:43 PM
$MDNAF I was also unaware that Dr Gwynne joined the team last November https://www.linkedin.com/posts/william-d-gwynne-phd-75a722132_excited-to-share-that-ive-joined-medicenna-activity-7396329961076215808-TlTW?utm_medium=ios_app&rcm=ACoAAAsnC8EBAcKQyUEEvVrkPzTEpnlOSa2bgnk&utm_source=social_share_send&utm_campaign=copy_link
1 · Reply
Lytnup
Lytnup Feb. 17 at 12:55 PM
$MDNAF Here’s to getting new eyes on Medicenna’s pipeline & promise https://open.substack.com/pub/davidbakke/p/from-biology-outpaced-to-execution?r=10wt7d&utm_medium=ios
0 · Reply
Biosectors
Biosectors Feb. 16 at 5:44 PM
$MDNAF Good morning all longs This is the crucial period of 3 days for Medicenna the best in class superkine and 113 with no toxicity at 30x and phase 3 ready on 55. This is a must for Merck to protect their oncology revenue till 2040 but they are cunning and sneaky to gobble this for as low as possible. I expect a bidding war starting Thursday don’t sell any of your holdings for 5 or 10 $ range this is worth a lot more. Let the market play it out and make sure Merck cannot pile up shares to start playing games later. The recent addition of 2 strategic heavyweights to the board is a master move they are experts in M&A and legal areas with strong roots and expertise even to raise money to shop around for a good return not crumbs. Merck is playing game to grab this based on low capital $$ now that may last till June July but they have other means to get this going and raise without dilution. Patience and hope long since 2022 and finally the days are coming through this week.
2 · Reply
Lytnup
Lytnup Feb. 15 at 4:01 PM
$MDNAF Some data points to absorb about the (2) recent additions to the BOD https://www.jcclark.com/team/ https://angelosgeorgakis.com/#testimonials Lingering question for me that I hope I can find an answer to in the next few months: in a cash-strapped situation, why would the company bring a 2nd compound to the clinic in addition to pursuing a registrational / pivotal trial on MDNA11?
0 · Reply
Gobblin
Gobblin Feb. 13 at 5:25 PM
$MDNAF My AI buddy re addition of new board members. Adding capital markets + inflection-point directors suggests: They are preparing for: • Either structured partnership • Or maximizing valuation into next data release Companies don’t upgrade boards like this just to drift.
0 · Reply
Biosectors
Biosectors Feb. 13 at 2:31 PM
$MDNAF Good morning and good luck If Merck doesn’t make a move in the next few days or up until conference the platform will be up for grabs by big guys is my gut feeling. This is the best news under the situation and circumstances for longs Medicenna is the only superkine best in its class and best data with keytruda combo or pd1 all others IL have failed Go figure why this news alters the whole paradigm here Have a nice Friday and long weekend all longs I am praying and hoping good news waiting since early 2022 with lot of patience
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Feb. 13 at 2:26 PM
$MDNAF 3d Q https://ir.medicenna.com/news-releases/news-release-details/medicenna-therapeutics-reports-third-quarter-fiscal-2026/
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Feb. 13 at 12:55 PM
$MDNAF Anyone’s thoughts on the new Board additions? Buyout prep or dilution !?! https://ir.medicenna.com/news-releases/news-release-details/medicenna-announces-changes-board-composition/
2 · Reply
Lytnup
Lytnup Feb. 11 at 5:59 PM
$MDNAF While we wait: Q3 numbers have historically been released this week; and David has published another article that has some interesting information on some trending items. https://open.substack.com/pub/davidbakke/p/pulse-check-update?r=10wt7d&utm_medium=ios
0 · Reply
Lytnup
Lytnup Feb. 10 at 6:24 PM
$MDNAF In the “For What It’s Worth” department - new 52-week low set.
2 · Reply
_Osmium
_Osmium Feb. 5 at 3:14 PM
$MDNAF A longtime holders sold and I can relate. He brought up a good point regarding MDNA11 vs THOR 707 so I thought I put this here. I'm surprised David (substack) didn't deep dive this more: THOR-707 (Sanofi) ✔ First-generation engineered IL-2 without IL-2Rα binding ✔ Showed expected immune bias in early trials ❌ Lower potency and clinical efficacy than hoped; program discontinued MDNA11 ✔ Next-generation IL-2 superkine with enhanced IL-2Rβ affinity and albumin fusion ✔ Demonstrates promising clinical responses and durable immune cell expansion ✔ Favorable safety and dosing profiles ✔ Still actively in Phase 1/2 development Bottom line: Both drugs share a common immuno-oncology strategy — leverage IL-2 signaling to stimulate anti-tumor immunity without triggering regulatory T cells and toxicities — but MDNA11’s enhanced receptor engagement and extended half-life appear to translate into stronger, more durable clinical activity compared with THOR-707’s earlier approach.
0 · Reply
Biosectors
Biosectors Feb. 4 at 11:03 PM
$MDNAF Sorry to hear the sequence of events that prompted you to exit this quality science and future of IL 2 space that Medicenna is on the verge of adding a huge value based on the recent findings and the internal external read out plus MDNA55 with phase 3 ready. I am hoping the conference next week in Boston will bring a lot more to the table and big guys like Merck or BMS may fund to carry on the path laid out. Wish you good luck and wish others here for a nice return in the months ahead. I am holding this entire year and then take a call. I loaded more in anticipation of some exciting data read out on 17-19 so it catches big guys attention. RA capital invested at around 1.45$ it’s at 65cents now, RA is a biotech shark they don’t invest without the potential and they exit with a profit hence I will hold till this whatever happens it’s ok.
2 · Reply
Spartrap
Spartrap Feb. 4 at 4:38 PM
$MDNAF fully out now. I wish you well longs. Dilution risk is getting too high now and I loathe the recent licensing of a bullshitting platform & general lower quality of scientific publications lately. That indicates a shift toward retail that rarely works out for investors. Toxic financing with warrant are sure to follow. If I had to do a forensic of my failed investment here, I'd say I downplayed way too much the risk induced by the co leaving the Nasdaq. The visibility and cred suffered immensely and it became extremely challenging for even a competent CEO to convey their message to the right ears. I came hot on the heels of the RA capital investment and it took me more than a year to understand RA were in fact simply betting on the success of Sanofi's THOR-707. When Sanofi abruptly discontinued their trials in October 24, the bet failed. I still see potential for 113 but the compound is too early. I don't like the probability of a deal there. It could happen though
2 · Reply
BigJon123
BigJon123 Feb. 1 at 7:04 PM
$MDNAF looking at David and PRISM-11’s licensing with MDNAF and what it means about his data - if MDNA is willing to pay money to make use of PRISM, is it because they agree with what David has published so far? Their internal data is matching his publishing (ie, PRISM has been correct)? If that is the case and PRISM has been right so far, the outlook is bright for bizaxofusp, MDNA 11 and 113!
2 · Reply